Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Community Practice Connections™: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma
October 18th 2024The FDA approved zolbetuximab-clzb plus fluoropyrimidine- and platinum-containing chemotherapy for patients with CLDN18.2-positive locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Looking Ahead: The Future of Chronic GVHD Management and Patient Care
October 7th 2024Panelists conclude by discussing the future of graft-versus-host disease management, expressing their hopes for the current treatment landscape and potential advancements that could further improve patient outcomes and quality of life.
Treatment with Axatilimab in Chronic GVHD: How it Works and Insights into Treatment Efficacy
October 7th 2024Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential role in cGVHD management and presenting key findings from the AGAVE-201 trial that demonstrate its efficacy and safety profile.